BioCentury

1:51 AM GMT, Feb 5, 2010
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Clinical News

Fidaxomicin meets Phase III endpoint

Optimer Pharmaceuticals Inc. (NASDAQ:OPTR) said fidaxomicin ( OPT-80) was non-inferior to Vancocin vancomycin on

Read the full 145 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.